Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

91.72 +0.03 (+0.03%)

Streaming Delayed Price Updated: 9:32 AM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations

October 24, 2025

Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,...

Via MarketMinute

Topics Government World Trade

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years ↗

October 23, 2025

Via MarketBeat

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership ↗

October 23, 2025

Via Benzinga

Topics Initial Public Offering

AstraZeneca’s Enhertu Achieves Record Response Rate In Phase 3 Trial For Early Breast Cancer ↗

October 20, 2025

Via Stocktwits

AstraZeneca Reportedly Nears Drug Pricing Deal With President Trump ↗

October 10, 2025

Via Stocktwits

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Danaher Corporation Poised for Growth as Q3 2025 Earnings Spark Optimism

October 22, 2025

Washington D.C., October 22, 2025 – Danaher Corporation (NYSE: DHR) is currently experiencing a wave of positive sentiment, with its stock price widely expected to rise following a robust third-quarter...

Via MarketMinute

Peering Into AstraZeneca PLC's Recent Short Interest ↗

October 22, 2025

Via Benzinga

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option

October 19, 2025

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

October 18, 2025

From AstraZeneca

Via Business Wire

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash ↗

October 18, 2025

AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.

Via Investor's Business Daily

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

October 18, 2025

From AstraZeneca

Via Business Wire

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

October 17, 2025

From AstraZeneca

Via Business Wire

Invo Fertility Stock Is Plunging After White House Announcement ↗

October 17, 2025

INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.

Via Benzinga

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

October 17, 2025

From AstraZeneca

Via Business Wire

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

October 17, 2025

From AstraZeneca

Via Business Wire

UK Finance Minister Seeks More Pharma Investment In Exchange For Higher Drug Prices: Report ↗

October 16, 2025

UK finance minister Rachel Reeves told reporters that the country needs to be an attractive place for pharma, including in terms of pricing.

Via Benzinga

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades ↗

October 16, 2025

These companies are investing heavily into their pipelines and the payoff for long-term investors can be substantial.

Via The Motley Fool

Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs ↗

October 15, 2025

Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.

Via Benzinga

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug ↗

October 15, 2025

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma.

Via Stocktwits

AstraZeneca unveils expanded manufacturing facility in Texas

October 15, 2025

From AstraZeneca

Via Business Wire

AstraZeneca PLC (NASDAQ:AZN): A Caviar Cruise Quality Investment ↗

October 15, 2025

Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages.

Via Chartmill

Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential ↗

October 14, 2025

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at least $5 billion.

Via Benzinga

Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?

October 13, 2025

Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to...

Via MarketMinute

Topics Artificial Intelligence

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

October 13, 2025

From AstraZeneca

Via Business Wire

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans ↗

October 10, 2025

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model.

Via Benzinga

Topics Government

UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investments ↗

October 10, 2025

UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.

Via Benzinga

Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation

October 09, 2025

New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...

Via MarketMinute

Topics Artificial Intelligence Economy Government

< Previous 1 2 3 4 5 6 7 8 9

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.